fda green list import alert 66-80 glp-1 GLP-1, List, Food and Drug Administration Issues
Description
reduce visceral, subcutaneous and liver fat contents
This can range from complete plan exclusion to complete coverage
Oral supplementation, for instance, often presents challenges in peptide degradation and limited bioactivity
In tirzepatide trials, reductions were often larger, with some analyses showing average decreases of 25 to 30% or more at higher doses
